[ad_1]
Francesco Storace
They removed the tricolor from the only true Italian vaccine. Without euro. It is not in the favor of those responsible. But at Takis, a biotech company fighting the coronavirus, they remain the same. Luigi Aurisicchio, the number one company, does not give up the anti-Covid vaccine, even if the rabies persists. When asked why institutions are not funding his research, the answer is harsh: ‘We don’t know. We have tried repeatedly to contact them without success. ‘
Takis has a turnover of around 2 million euros with double-digit annual growth rates, collaborates with large groups and has recently been the first in the selection made by the Enea agency of 21 innovative projects in partnership. In the experimental work of the Covid-19 vaccine, she uses all the accumulated experience in immunotherapy against cancer. In Takis they have begun the preclinical phase to identify a vaccine against the coronavirus. They are the first in Italy and have launched a crowdfunding initiative that, in less than a week, has allowed the collection of 24-25 thousand euros. Then still another (little) money. A fall, however, with respect to the economic needs corresponding to the objective of bringing experimentation to man, estimated at at least 2 million.
Aurisicchio avoids controversy, does not seek it, but his words show the typical bitterness of those who feel unmotivated hostility in their native land. Takis was associated with Spallanzani. At some point it seems that the collaboration was interrupted. He denies it. Collaboration has never stopped. We had not yet received an official report of the data they generated. And then we ask where the Takis vaccine research is. You can start counting progress: “We are successfully completing the preclinical / regulatory phase. At the end of November-beginning of December we will start the clinical study in Naples, Rome and Monza ». The state focuses on Reithera, the company owned by a Swiss company that collaborates with the multinational Glaxo.
Luigi Aurisicchio becomes a true diplomat when we ask him about production differences. “Our vaccine is not a modified virus but a DNA fragment that is administered after electrostimulation. It can be administered many times unlike those based on viral vectors. But even this costs, how do you do if no one helps you? (However, the initial phase of vaccine research, for now, they manage to fund). After an initial crowdfunding of around 50 thousand euros, we have started an exceptional collaboration with Rottapharm biotech that covers expenses and contributes to its team ”.
Voices gathered in the vicinity of the Palazzo Chigi point to the man who must identify the “strategic” companies in which the State can enter with its own shares in Commissioner Domenico Arcuri. Takis could also be “recruited”. But no. “We could. But so far no one has contacted us.”
It’s not around here. Dr. Aurisicchio, have the institutions supported you, in particular the Region and the Ministry of Research? Dry, almost annoying, his “no”. And is there not a reason, a reason, for the lack of financial support? “Unmotivated. We were told that the viral vector technologies already used for Ebola were more ‘validated’.”
Perhaps it was enough to meet the Lazio Councilor for Health, Alessio D’Amato, it seems that it was he who convinced Zingaretti about the Italian vaccine that he is not Italian at all and yet he did not realize the work that the team was doing to Reithera’s stone’s throw by Aurisicchio. “No, I don’t know him.”
Who knows, maybe they are too Italian, without Swiss connoisseurs … «Let’s say that we are advancing with our forces until clinical phase 2, but then we will necessarily have to have a contribution from Italy or Europe. Otherwise, we will have to look abroad.
[ad_2]
